

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: October 12, 2011
(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-32188
(Commission
File Number)

59-3410522
(IRS Employer
Identification Number)

**3000 Bayport Drive, Suite 685
Tampa, FL**
(Address of principal executive offices)

33607
(Zip Code)

813-286-7900
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On October 12, 2011, Oragenics, Inc. (the "Company") and Dr. Jeffrey D. Hillman entered into a Separation and Release Agreement ("Separation Agreement") which provides for Dr. Hillman's retirement from full time service to the Company and his resignation as Chief Scientific Officer and as a director of the Company, effective October 31, 2011.

Pursuant to the terms of the Separation Agreement Dr. Hillman will receive an award of 120,000 restricted shares of Company common stock subject to performance as well as time based vesting. The performance based vesting relates to the completion of certain work-in-progress concerning Company intellectual property and the time vesting is equal over a three year period with the restricted shares being subject to earlier vesting upon a change of control. The Separation Agreement also provides for the amendment of Dr. Hillman's outstanding stock option agreements to (a) vest any unvested options and (b) extend the exercise period of such options for one year post separation of employment until October 31, 2012.

In addition and notwithstanding Dr. Hillman's retirement, Dr. Hillman is expected to continue to be available to provide services to the Company as a consultant pursuant to the terms of a consulting agreement he entered into simultaneously with the Separation Agreement that takes effect immediately following the effective date of Dr. Hillman's retirement. Under the terms of the Consulting Agreement, Dr. Hillman will continue to provide services to the Company for a six month period, for which Dr. Hillman will be compensated at an hourly rate for a limited number of hours over such period and on terms mutually agreed to after such limit has been reached.

Dr. Hillman's retirement and resignation was due to his decision to retire and was not related to any disagreement or dispute with the Company's management.

A copy of the October 14, 2011 press release announcing the retirement and resignation of Dr. Hillman as chief scientific officer is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

(d) Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Press Release dated October 14, 2011.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 14th day of October, 2011.

ORAGENICS, INC.
(Registrant)

BY: /s/ Brian Bohunicky
Brian Bohunicky
Chief Financial Officer



Oragenics Announces Retirement of Dr. Jeffrey Hillman

For Immediate Release

Tampa, FL (October 14, 2011) – **Oragenics, Inc.** (OTCBB: ORNI.OB www.rogenics.com), a biopharmaceutical company (the “Company”), announced today that its founder and Chief Scientific Officer, Dr. Jeffrey Hillman, will retire from full time service to the Company and as a director, effective October 31, 2011. Following Dr. Hillman’s separation from the Company as an employee and director, he has agreed to continue to be available to assist the Company as a consultant.

Dr. Hillman stated “For the past fifteen years, Oragenics has been a significant part of my life and it will remain so. While the work of developing the Company’s technologies has been very important to me, I believe this is the right time for me to take a less active role and I look forward to assisting Oragenics in my new role as a consultant.” Dr. Hillman continued “I believe Oragenics has tremendous potential with its currently marketed ProBiora3 oral probiotic products, its SMaRT Replacement Therapy technology and a pipeline of novel antibiotic candidates. I have full confidence in the Company’s leadership and believe that Oragenics’ brightest days are ahead.”

Dr. Hillman co-founded the Company in 1996 and is the inventor of Oragenics’ technologies. Dr. Hillman has served as our Chief Scientific Officer and as a Director since November 1996.

Dr. Frederick Telling, the Company’s Chairman said, “Dr. Hillman has brought to the Company an extensive background spanning over 30 years in biotechnology research and development and a deep knowledge and understanding of Oragenics’ technology, and business. All of us at Oragenics are grateful for his knowledge and dedicated commitment throughout our journey to get us where we are today. We wish him the best in his retirement.”

“Dr. Hillman’s vision and work ethic have had a significant impact on Oragenics,” said Dr. John Bonfiglio, President and Chief Executive Officer of Oragenics. “We are all proud to be a part of the legacy he has built, both within the Company and in the communities we serve, and we offer him our most sincere gratitude for his years of service.”

About Oragenics, Inc.

Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is developing its pharmaceutical product candidate, SMaRT Replacement Therapy, and also commercializing its oral probiotic product, ProBiora3. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S and intends to use its patented, novel organic chemistry platform to create additional antibiotics for therapeutic use.

Safe Harbor Statement: *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

MEDIA CONTACT: *For more information about the company, visit www.rogenics.com or contact Brian Bohunicky at (813) 286-7900.*